We came across a bullish thesis on Tempus AI, Inc. on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.’s share was trading at .57 as of January 28th. TEM’s trailing P/E was 41.53 according to Yahoo Finance.

Tempus AI, Inc. (NASDAQ: TEM) operates at the forefront of precision medicine, combining high-throughput genomic diagnostics with advanced AI technology. The company has built one of the world’s largest multimodal datasets in oncology and cardiology, integrating clinical, molecular, and imaging data. This unique dataset drives its high-margin Data & Services segment, which licenses insights to pharmaceutical partners for drug discovery and clinical trial optimization, creating a recurring revenue stream that subsidizes its lower-margin genomics testing.

The acquisition of Ambry Genetics in early 2025 expanded Tempus’s germline testing capabilities, while the purchase of Paige.AI added digital pathology and AI-driven slide analysis, further strengthening its data moat. These moves have created a “flywheel” effect, where diagnostic operations feed the data business, which in turn funds growth and innovation. Financially, Tempus reached positive Adjusted EBITDA in Q3 2025, marking a critical inflection point.

Gross margins are improving toward software-like levels, with the Data & Services segment approaching 70% margins. The balance sheet is strong, with $764 million in cash and low-cost convertible debt, giving the company flexibility for further growth or strategic acquisitions. The stock currently trades at $64, providing an attractive entry point given the company’s robust growth trajectory, recurring revenue model, and expanding competitive advantage.

Source: Tempus AI, Inc. (TEM): A Bull Case Theory